Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer

AIMS: The Medical Research Council OVO5/EORTC 55955 trial showed that patients in remission after first-line therapy for ovarian cancer did not benefit from routine measurement of CA125 during follow-up. Since the presentation of these results, we have counseled patients about the options for follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Krell, Daniel, Said Battistino, Fran, Benafif, Sarah, Ganegoda, Lochani, Hall, Marcia, Rustin, Gordon J.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Ovarian Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499967/
https://www.ncbi.nlm.nih.gov/pubmed/28333841
http://dx.doi.org/10.1097/IGC.0000000000000956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499967/
https://www.ncbi.nlm.nih.gov/pubmed/28333841
http://dx.doi.org/10.1097/IGC.0000000000000956

Ejemplares similares